Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

Open access
Vansteenkiste, Johan F., Canon, Jean-Luc, De Braud, Filippo, Grossi, Francesco, De Pas, Tommaso, Gray, Jhanelle E., Su, Wu-Chou, Felip, Enriqueta, Yoshioka, Hiroshige, Gridelli, Cesare, Dy, Grace K., Thongprasert, Sumitra, Reck, Martin, Aimone, Paola, Vidam, Gena Atalla, Roussou, Pantelia, Wang, Ying A., Di Tomaso, Emmanuelle, Soria, Jean-Charles · 2015 · Journal of Thoracic Oncology

Abstract

INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients with PI3K pathway-activated, relapsed NSCLC. METHODS: After prescreening for PI3K pathway activation, patients with PI3K pathway-activated, metastatic, squamous or nonsquamous NSCLC, who had relapsed after prior systemic antineoplastic therapy, were enrolled. In Stage 1, patients received single-agent buparlisib (100 mg/day). A futility analysis was performed independently in each histology group, based on the 12-week progression-free survival rate for the first 30 patients treated in each group being less than 50%. Exploratory biomarker analyses were performed in archival tissue samples and circulating tumor DNA (ctDNA). RESULTS: Of 1242 prescreened patients, 13.5% exhibited PI3K pathway activation. As of June 5, 2014, 63 patients (30 squamous and 33 nonsquamous) were treated in Stage 1. The 12-week progression-free survival rates were 23.3% (95% confidence interval: 9.9-42.3) and 20.0% (95% confidence interval: 7.7-38.6) in the squamous and nonsquamous groups, respectively. Stage 2 was therefore not initiated in either group. PI3K pathway mutations in ctDNA were more concordant with metastatic tissue than with primary biopsies. CONCLUSIONS: Despite preselecting patients for targeted treatment, BASALT-1 did not meet its primary objective during Stage 1. PI3K pathway activation can be detected using ctDNA, but may not be the main oncogenic driver in NSCLC. Combinations of PI3K inhibitors with other agents may demonstrate greater efficacy than monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000607

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 162

Metadata

Authors
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., Dy, G. K., Thongprasert, S., Reck, M., Aimone, P., Vidam, G. A., Roussou, P., Wang, Y. A., Di Tomaso, E., & Soria, J.-C.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2015-09
Volume
10
Issue
9
Pages
1319-1327
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2238997491
Cited by
162
References
5
FWCI
15.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1097/jto.0000000000000607
The paper
Vansteenkiste, J. F., Canon, J.-L., De Braud, F., Grossi, F., De Pas, T., Gray, J. E., Su, W.-C., Felip, E., Yoshioka, H., Gridelli, C., Dy, G. K., Thongprasert, S., Reck, M., Aimone, P., Vidam, G. A., Roussou, P., Wang, Y. A., Di Tomaso, E., & Soria, J.-C. (2015). Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0000000000000607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.